NanoViricides, Inc. (NYSE American: NNVC), a clinical-stage company developing antiviral drugs, has announced additional details regarding its Phase II clinical trial of NV-387 Oral Gummies for the treatment of the current Bundibugyo Ebolavirus (BDBV) outbreak and other Ebola viruses in the Democratic Republic of Congo. According to the company, the trial is proceeding as designed, with enrollment in Phase IIA beginning on or about September 23, 2026. Phase IIA is intended to identify an optimal, well-tolerated dosing regimen and serve as a go/no-go step before Phase IIB, a randomized controlled trial designed to evaluate efficacy.
NV-387 is designed to attack the virus and reduce viral load, and is delivered as an oral gummy that dissolves in the mouth without requiring water or swallowing effort. The company noted that, if successful, the oral treatment could be readily deployed in resource-limited settings. NanoViricides characterized NV-387 as a broad-spectrum antiviral that mimics a host-side feature used by Ebola viruses and said there is a rationale for potential activity against Bundibugyo and other Ebola viruses. For more details, the full press release is available at https://ibn.fm/zjg8X.
The development of an oral antiviral for Ebola could have significant implications for global health. Current Ebola treatments often require intravenous administration, which can be challenging in outbreak settings where medical infrastructure is limited. An oral gummy that dissolves in the mouth could simplify distribution and administration, potentially improving patient access and outcomes. The Phase IIA trial will assess safety and dosing, while the subsequent Phase IIB trial will evaluate efficacy. If successful, NV-387 could become an important tool in combating Ebola outbreaks, particularly in remote areas of the Democratic Republic of Congo and beyond.
NanoViricides is a clinical-stage company creating special purpose nanomaterials for antiviral therapy. Its novel nanoviricide class of drug candidates is based on intellectual property, technology, and proprietary know-how of TheraCour Pharma, Inc. The company has a Memorandum of Understanding with TheraCour for the development of drugs based on these technologies for all antiviral infections. The company's business model is based on licensing technology from TheraCour Pharma Inc. for specific application verticals of specific viruses. The lead drug candidate, NV-387, is a broad-spectrum antiviral being developed for RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox infections, and even Measles. Another advanced drug candidate is NV-HHV-1 for the treatment of Shingles. The company is also developing drugs against a number of viral diseases including oral and genital Herpes, viral diseases of the eye, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others. More information about the company can be found at www.nanoviricides.com.
The latest news and updates relating to NNVC are available in the company's newsroom at https://ibn.fm/NNVC. This announcement was distributed by BioMedWire, a specialized communications platform with a focus on the latest developments in the Biotechnology, Biomedical Sciences, and Life Sciences sectors. BioMedWire is one of 75+ brands within the Dynamic Brand Portfolio at IBN that delivers access to a vast network of wire solutions via InvestorWire, among other services. For more information, visit https://www.BioMedWire.com. The full terms of use and disclaimers are available at https://www.BioMedWire.com/Disclaimer.
